Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And in fact, we have been able to deliver strong predictive models with high levels of accuracy |
| And we are very excited to be at the forefront of AI and early drug discovery, playing an important role in the discovery of new oncology drugs, which we believe will not only benefit patients but also create enduring value for our shareholders as well |
| We hope that you take away from this call that the entire Predictive Oncology team is very excited about the growth trajectory that we are currently on |
| And he has already had a positive impact on helping some of our operating businesses focus more on top line growth and profitability, introducing efficiencies in the finance and accounting department and helping roll out a more robust Investor Relations program |
| I point this out because this company is well positioned to generate near-term formulations revenue to supplement building a pipeline of milestone-driven PEDAL contracts |
| And this relationship has had a very positive impact on our business development efforts elsewhere |
| I am pleased with our progress to date and believe we have created a solid foundation on which to drive future growth |
| These contracts point to the versatility of our technology to positively impact a broad spectrum of early drug discovery and development projects |
| We have no long-term debt, so our balance sheet is strong |
| As our momentum continues to accelerate, the Business Advisory Board's insight, expertise and perspectives will be invaluable in our efforts to deliver unique solutions to our drug development partners and creating lasting value for our shareholders |
| Not unlike the efficient predictive accuracy of the PEDAL platform for drug discovery, our biologics capabilities enable us to efficiently streamline and accelerate the formulation process, identify alternative and more viable formulations for commercial production and drug discovery applications |
| Ultimately, these models could support the tailoring of therapies to individual patients with the goal of positively affecting the overall survival of ovarian cancer patients and the development of invaluable clinical support tools |
| But with our unique capabilities, our partners can gain insight into the future of heterogeneous drug response and confidently make strategic clinical drug development decisions with lower financial risk and greater likelihood of commercial success |
| Today, I am pleased to announce that we have provided CRH with the initial results of this research collaboration, which, as you might imagine, is a very significant milestone for our company, not only in terms of the results themselves, but because we were able to achieve these results in a matter of weeks |
| And we are at the forefront of this exciting and foundational transformation |
| As a reminder, CRH is the innovative engine at the core of Cancer Research UK, the largest independent funder of cancer research in the world |
| Separately but simultaneously, we have successfully developed a novel formulation for a protein drug candidate for an international pharmaceutical company that enabled that company to proceed with their toxicology studies |
| With our proprietary biobank of more than 150,000 tumor samples and CLIA-certified wet labs, we believe we can predict with a higher degree of accuracy than anyone else the probability of clinical success because we were able to introduce patients and tumor heterogeneity into the very earliest stages of drug development |
| In March of this year, we were very pleased to announce a research collaboration with Cancer Research Horizons, whereby we would utilize our AI drug discovery platform, our PEDAL platform, to evaluate several CRH preclinical glutaminase inhibitor drug compounds to determine which cancer types and patient populations are most likely to respond to treatment with these compounds |
| First, because we are now eligible for development and commercialization milestones in the event that a licensing deal is executed as well as potential sales royalties; and second, because we believe the success of this first campaign, which, as I said, was completed in several weeks, should pave the way for additional projects from CRH |
| I'm pleased to have Josh on board |
| Clearly, there's an opportunity here to explore drug rescue or repurposing for the treatment of ovarian cancer and in the process of discovery and development, identify significant intellectual property that is specific to these predictive models and beneficial to an AI-driven decision support platform |
| The objective of this collaboration was to leverage and maximize the combined power of Predictive Oncology's expertise in artificial intelligence and Cvergenx proficiency in biomarker development for radiation therapy to identify novel radioprotector and radiosensitizer drugs |
| Raymond? Raymond Vennare Glenn, thank you very much, and good morning, everyone |
| For example, we continue to make progress on a novel method to express and stabilize GPCR, G protein-coupled receptors, which is an important class of membrane proteins that represent an emerging market in cancer drug discovery |
| Have a good day |
| High-grade serous carcinomas, for example, of the ovary make up most ovarian cancer cases and have the lowest survival rate |
| We announced just last week that we have successfully completed a multiyear retrospective study with UPMC Magee-Women’s Hospital in Pittsburgh |
| Thank you for joining us |
| By prioritizing the development of the strongest candidates for the ideal tumor types based upon the output from PEDAL, CRH can save significant time and resources by pursuing only those projects that are most likely to succeed in the clinic |
| Statement |
|---|
| Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors, including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC |
| This is significant for two reasons |
Please consider a small donation if you think this website provides you with relevant information